A5054060045- Clinical Nutrition and Gastroenterology
- Inflammatory Bowel Disease
- Nutrition and Health in Aging
- Microscopic Colitis
- Abdominal Surgery and Complications
- Metabolism and Genetic Disorders
- Diet and metabolism studies
- Central Venous Catheters and Hemodialysis
- Intestinal Malrotation and Obstruction Disorders
- Dialysis and Renal Disease Management
- Pharmaceutical studies and practices
- Folate and B Vitamins Research
- Organ Transplantation Techniques and Outcomes
- Pediatric Hepatobiliary Diseases and Treatments
- Intestinal and Peritoneal Adhesions
- Eosinophilic Esophagitis
- Helicobacter pylori-related gastroenterology studies
- Liver Disease and Transplantation
- Child Nutrition and Feeding Issues
- Digestive system and related health
- Gastrointestinal disorders and treatments
- Electrolyte and hormonal disorders
- Pharmacological Effects and Toxicity Studies
- Infective Endocarditis Diagnosis and Management
- Infant Nutrition and Health
University of Illinois Chicago
2006-2024
University of Illinois Hospital & Health Sciences System
2019-2024
Health Care Service Corporation
2018-2019
Northwestern University
2005-2015
Glenbrook Hospital
2012-2013
Development Fund
2011
Northwestern Memorial Hospital
2005-2010
Quest Diagnostics (United States)
2010
Division of Chemistry
2008
The University of Texas Health Science Center at Houston
1997-2007
<b>Background and aims:</b> Glucagon-like peptide 2 (GLP-2) may improve intestinal absorption in short bowel syndrome (SBS) patients with an end jejunostomy. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant GLP-2 analogue, prolongs the intestinotrophic properties of animal models. The safety effect teduglutide were investigated SBS without colon continuity. <b>Methods:</b> was given subcutaneously for 21 days once or twice daily to 16 per protocol investigational group, 10...
Background: Numerous animal studies have demonstrated intestinal villus atrophy occurs when luminal nutrition is withheld and total parenteral (TPN) provided. Intestinal morphologic functional changes not been well studied in humans during TPN. Methods: Eight normal volunteers were hospitalized the Clinical Research Center for 3 weeks. The subjects received TPN as an exclusive means of nutritional support 14 days followed by 5 enteral refeeding with either a standard or glutamine...
The parenteral multivitamin preparations that are commercially available in the United States (U.S.) meet requirements for most patients who receive nutrition (PN). However, a separate vitamin D preparation (cholecalciferol or ergocalciferol) should be made treatment of with deficiency unresponsive to oral supplementation. Carnitine is and routinely added neonatal PN formulations. Choline also adult pediatric formulations; however, product needs developed. multi-trace element (TE) U.S....
Patients receiving long-term total parenteral nutrition (TPN) develop hepatic steatosis as a complication. Our previous studies have shown this to be caused, at least in part, by choline deficiency. We studied four patients (1 man, 3 women) aged 50 +/- 13 years who had low plasma-free concentrations 4.8 1.7 (normal, 11.4 3.7 nmol/mL). The received TPN for 9.7 4.7 years. They solutions containing chloride 4 g/d) 6 weeks. Abdominal computed tomography (CT) was performed baseline, biweekly...
Second Annual Snowbird Conference on Clinical Management of Inflammatory Bowel Diseases and Intestinal Failure March 9–12, 2006
Background: Previous studies have shown that plasma free choline concentrations are significantly decreased in many long‐term home total parenteral nutrition (TPN) patients. Furthermore, low status has been associated with both hepatic morphologic and aminotransferase abnormalities. A preliminary pilot study suggested choline‐supplemented TPN may be useful reversal of these Methods: Fifteen patients (10 M, 5 F) who had required for >80% their nutritional needs were randomized to receive...
Background and aims: To evaluate the safety efficacy of intercellular adhesion molecule 1 (ICAM-1) antisense phosphorothioate oligonucleotide alicaforsen (ISIS 2302) in Crohn's disease. Methods: Active (Crohn's disease activity index (CDAI) 200–350), steroid dependent (prednisone 10–40 mg) patients were randomised into three treatment groups: placebo versus ISIS 2302 (2 mg/kg intravenously times a week) for two or four weeks. Patients treated months 3, with withdrawal attempted by week 10....
The women's health aspect of inflammatory bowel disease (IBD) is a newer area study; childbearing issues have received little attention despite the fact that IBD affects women predominantly during their years. aim this study was to better understand patients' considerations about pregnancy-related and examine trends in so physicians are able tailor advice IBD-specific concerns.Data were gathered from specific questions 3147 surveys mailed anonymously all members Crohn's Colitis Foundation...
OBJECTIVES: Historically, suspected Crohn's disease (CD) has been evaluated with small bowel follow-through (SBFT) or enteroclysis (equally accurate). This study was undertaken to determine the accuracy of videocapsule endoscopy (VCE) in diagnosis CD relative SBFT and clinical/laboratory indices activity. Previous investigations have used VCE for patients presenting a variety gastrointestinal symptoms. is first evaluate occurrence active known CD. METHODS: Thirty subjects (22 female, 8 male,...
Teduglutide, an analog of glucagon-like peptide-2 (GLP-2), is associated with trophic effects on gut mucosa. Its role in the treatment active Crohn's disease (CD) was assessed a pilot, randomized, placebo-controlled, double-blinded, dose-ranging study.Subjects moderate-to-severe CD were randomized 1:1:1:1 to placebo or 1 3 doses teduglutide (0.05, 0.10, 0.20 mg/kg daily) delivered as daily subcutaneous injection for 8 weeks. The primary outcome measure percentage subjects each group that...
The inpatient and outpatient records were reviewed for 527 patients, including 138 children, who discharged on home total parenteral nutrition followed by the University of California, Los Angeles, service a minimum 1 week between April 1973 October 1991. follow-up time was 1154 patient years; median 206 days (range 7 to 6344 days). Thirty-six patients more than 10 years (median 12.7 years). Three hundred fifteen adults (but only four children) never infected. A 427 catheter-related...